Allogeneic Vs. Autologous Cell Therapy: Deciding On Your Product Strategy

Cell therapy development and manufacturing can be divided into two categories, autologous and allogeneic methods, both of which have unique benefits, limitations, and future opportunities to consider.

In this expanding industry, autologous is the traditional vehicle for treating patients and offers some specific benefits for both developers and the patients they are serving. Allogeneic is seen by many as the future for cell therapy drug products, but there are potential risks associated with any new method of pharmaceutical development.

Which is the best one for your future drug product? In this article, explore a few considerations that developers should keep in mind as they design their next cell therapy treatment.